1. 0379: Difference in the Natural History of Intraepithe- Lial Neoplasia Grade 1 (Cin1) By Human Papilloma- Virus (Hpv) Infection and Hpv-Dna Type in Japanese Women. (1st October 2006) Authors: Oda, T.; Fujiwara, K; Nagao, S.; Kagawa, R; Kozuka, Y.; Maehata, K; Nakata, T.; Kumazawa, K; Kohno, I. Journal: International journal of gynecological cancer Issue: Volume 16(2006)Supplement 3 Page Start: 708 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1473PImmune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients. (23rd October 2018) Authors: Kubo, T; Watanabe, H; Ninomiya, K; Kudo, K; Minami, D; Murakami, E; Ochi, N; Ninomiya, T; Harada, D; Yasugi, M; Ichihara, E; Ohashi, K; Fujiwara, K; Hotta, K; Tabata, M; Maeda, Y; Kiura, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 148 Senticol III: international validation study of sentinel node biopsy in early cervical cancer. A gineco, engot and gcig study. (18th September 2019) Authors: Lecuru, F; Mc Comack, M; Hillemans, P; Anota, A; Leitao, M; Sweemer, R; Fujiwara, K; Mathevet, P; Zanagnolo, V; Raza Mirza, M; Ferron, G; Plante, M; Balaya, V Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1 Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial. (13th November 2020) Authors: Ledermann, J; Colombo, N; Oza, A; Fujiwara, K; Birrer, MJ; Randall, L; Poddubskaya, E; Scambia, G; Shparyk, YV; Lim, MC; Lim, MC; Sohn, J; Yonemori, K; Stewart, RA; Zhang, X; Perkins Smith, J; Linn, C; Monk, BJ Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 263TiPATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer. (24th November 2019) Authors: Fujiwara, K; Chou, H-H; Kim, J-W; Tan, D S; Tamura, K; Katsumata, N; Harano, K; Hasegawa, K; Hume, S; Jones, E; Goble, S; Sullivan, L; Shih, D; Coleman, R L; McNeish, I; Monk, B; Kristeleit, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 264TiPENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer. (24th November 2019) Authors: Fujiwara, K; Vergote, I B; Sehouli, J; Salutari, V; Zola, P; Madry, R; Wenham, R M; Korach, J; Pautier, P; Cibula, D; Lheureux, S; Hasegawa, K; Kim, B-G; Lai, C-H; Gonzalez-Martinez, A; Liu, Q; Keefe, S M; Puglisi, M; Topuz, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 265TiPKEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer. (24th November 2019) Authors: Fujiwara, K; Shapira-Frommer, R; Alexandre, J; Monk, B; Fehm, T; Colombo, N; Caceres, M V; Hasegawa, K; Dubot, C; Li, J J; Stein, K; Keefe, S M; Tewari, K Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 391 Development of the comprehensive score for financial toxicity (COST) tool and assessment of financial toxicity in patients with gynecologic cancer in japan. (18th September 2019) Authors: Kajimoto, Y; Honda, K; Fujiwara, K; Mizuno, M; Nishimura, T; Fujiwara, H; Koyanagi, T; Kohara, I; Tamaki, S; Igarashi, A Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 934OAlienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse. (23rd October 2018) Authors: Ray-Coquard, I L; Harter, P; Lorusso, D; Dalban, C; Vergote, I B; Fujiwara, K; Gladieff, L; Lueck, H-J; Floquet, A; Lesoin, A F; Schnelzer, A; Pignata, S; Selle, F; Sehouli, J; Brocard, F; Mangili, G; Pautier, P; De Giorgi, U; Provansal, M; Heudel, P-E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. APPLICABILITY OF AUTONOMOUS UNMANNED HELICOPTER SURVEY OF AIR DOSE RATE IN SUBURBAN AREA. Issue 3 (16th May 2019) Authors: Yoshimura, K; Fujiwara, K; Nakama, S Journal: Radiation protection dosimetry Issue: Volume 184:Issue 3/4(2019) Page Start: 315 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗